Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells
Anticancer Research · 2024
DOI: 10.21873/anticanres.17303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Sei Morinaga und 13 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Docetaxel, Osteosarcoma, Drug Resistance, Neoplasm, Carbon-Sulfur Lyases. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AntiCancer Inc., San Diego, CA, U.S.A.
- Department of Surgery, University of California, San Diego, CA, U.S.A.
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
- AntiCancer Inc., San Diego, CA, U.S.A.; meishale@gmail.com.
Zitieren
APA
Morinaga, S., Han, Q., Mizuta, K., Kang, B. M., Bouvet, M., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Higuchi, T., Tsuchiya, H., Demura, S., & Hoffman, R. M. (2024). Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells. Anticancer Research. https://doi.org/10.21873/anticanres.17303
Vancouver
Morinaga S, Han Q, Mizuta K, Kang BM, Bouvet M, Yamamoto N, et al. Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells. Anticancer Research. 2024. doi:10.21873/anticanres.17303
BibTeX
@article{Morinaga2024,
author = {Morinaga, Sei and Han, Qinghong and Mizuta, Kohei and Kang, Byung M and Bouvet, Michael and Yamamoto, Norio and Hayashi, Katsuhiro and Kimura, Hiroaki and Miwa, Shinji and Igarashi, Kentaro and Higuchi, Takashi and Tsuchiya, Hiroyuki and Demura, Satoru and Hoffman, Robert M},
title = {Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17303}
}
EUVIMED